Author: Brad Chapman, Head of U.S. Epilepsy and Rare Syndromes, UCB | Hear from UCB’s Brad Chapman on the importance of inclusion, representation, and understanding in epilepsy and rare syndromes ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
After asset purchase from Travere, Mirum's Ctexli crosses FDA finish line in rare metabolic disorder
The approval makes chenodiol—already cleared for decades to treat radiolucent gallstones under the brand name Chenodal—the ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...
A new awareness campaign from Abbott highlights a major sticking point in diabetes management: the harmful impact of societal ...
With a $430 million buyout of Australia’s Mayne Pharma locked down, Cosette Pharmaceuticals is looking to become a leading ...
A popular awareness campaign now in its second year that encouraged people to get flu vaccines to reduce their risk of severe ...
Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback